Sanofi to acquire immuno-oncology company Synthorx for $2.5B
The San Diego-based biotech is developing IL-2 therapeutics for cancers as well as autoimmune disorders. Its lead candidate, THOR-707, is in a Phase I/II study in solid tumors.
Gilead to seek FDA approval for rheumatoid arthritis drug this year
The timing of the filing appears to allay concerns that the FDA would require completion of a study evaluating the testicular safety of the drug, filgotinib, and thus push its launch date from 2020 to 2021-22, an analyst wrote.
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
BMS to sell $1.6B psoriasis drug to satisfy FTC concerns about Celgene acquisition
The drugmaker said Monday it would sell off the drug Otezla to address concerns about competition that the Federal Trade Commission had expressed in connection to the pending $74 billion deal. According to an analyst, BMS saw Otezla as competitive against its investigational TYK2 inhibitor.
Gilead, Galapagos’s filgotinib scores in Phase III rheumatoid arthritis trial, but questions remain
Whether the FDA requires completion of a study to look at testicular toxicity before approval could dictate whether the drug launches next year or as late as 2022, an analyst wrote.
RNA metabolism-focused Gotham Therapeutics launches with $54M Series A round
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK's venture capital arm, Celgene and others.
Harbour BioMed raises $85M in Series B funding round
The company has been busy forming development and commercialization partnerships with other firms to develop antibodies in oncology and rheumatology.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
SQZ Biotech raises $72M in Series C funding round
The company will use funding to bring cell therapies into clinic in oncology and autoimmune indications.
Sangamo buys stake in French firm developing cell therapies for autoimmune disease
Sangamo purchases 53 percent of France-based TxCell, will use zinc finger nuclease technology to develop CAR-Treg cells.
NASDAQ bound: Argenx eyes a $75 million IPO
The unassuming llama may be the star of a new $75 million initial public offering, announced Monday by the Netherlands and Belgium-based biotech argenx.
aTyr Pharma orchestrates clean sweep of Physiocrine patents
Scripps spin-out aTyr Pharma announced Monday that it had rounded out its patent estate covering a full suite of signaling enzymes known as Physiocrines. It's good news for aTyr, but will the IP monopoly slow the wider field down?
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Can Aurinia’s modified lupus drug really make a difference?
Aurinia Pharmaceuticals took an existing drug and made just one amino acid modification. Is it another meaningless iteration, or could this drug really deliver major gains in lupus nephritis?
Celgene acquires autoimmune startup Delinia for $775M
On Thursday, Summit, New Jersey-based Celgene announced plans to acquire Delinia for an upfront $300 million and an additional $475 million in milestone-based payments. Delinia has a preclinical program that could be applied to a range of autoimmune diseases.